Abstract
Molecular markers for surveillance of Plasmodium falciparum resistance to current antimalarials are sorely needed. A 28-day efficacy study of artemether-lumefantrine in eastern Sudan identified 5 treatment failures among 100 evaluable patients; 9 further individuals were parasite positive by PCR during follow-up. Polymorphisms in pfatpase6 and pfmdr1 were evaluated by DNA sequencing. One individual carried parasites with a novel pfmdr1 polymorphism (F1044L). pfmdr1 gene amplification in parasites prior to treatment occurred in three individuals who had recurrent infection during follow-up.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antimalarials / therapeutic use*
-
Artemether, Lumefantrine Drug Combination
-
Artemisinins / therapeutic use*
-
DNA Copy Number Variations / drug effects
-
DNA Copy Number Variations / genetics
-
Drug Combinations
-
Ethanolamines / therapeutic use*
-
Female
-
Fluorenes / therapeutic use*
-
Haplotypes
-
Humans
-
Longitudinal Studies
-
Malaria / drug therapy*
-
Malaria / parasitology
-
Male
-
Multidrug Resistance-Associated Proteins / genetics*
-
Plasmodium falciparum / drug effects
-
Plasmodium falciparum / genetics*
-
Plasmodium falciparum / pathogenicity
-
Polymerase Chain Reaction
-
Polymorphism, Genetic / drug effects
-
Polymorphism, Genetic / genetics
-
Young Adult
Substances
-
Antimalarials
-
Artemether, Lumefantrine Drug Combination
-
Artemisinins
-
Drug Combinations
-
Ethanolamines
-
Fluorenes
-
Mdr1 protein, Plasmodium falciparum
-
Multidrug Resistance-Associated Proteins